Suppression of RPL34 Inhibits Tumor Cell Proliferation and Promotes Apoptosis in Glioblastoma

Appl Biochem Biotechnol. 2022 Aug;194(8):3494-3506. doi: 10.1007/s12010-022-03857-0. Epub 2022 Apr 4.

Abstract

Accumulating evidence indicates Ribosomal protein 34 (RPL34) promotes tumor malignance and its expression is associated with poor prognosis in multiple cancer cells. However, the physiological role and biological mechanism of RPL34 in glioblastoma (GBM) remain unclear. Hence, this study aimed to investigate the expression and the role of RPL34 in GBM. A total of 59 glioma samples and 12 normal brains for epilepsy surgery were used to determine the underlying mechanisms and the biological behaviors of RPL34 in GBM. In this study, we identified that RPL34 expression was significantly (p < 0.05) enriched in GBM tumors compared with low-grade glioma and normal brain, and its expression was associated with poor survival. Additionally, RPL34 was functionally required for tumor proliferation in vitro. Mechanically, inhibition of RPL34 induced glioma cell apoptosis by activation of Bad/Caspase7/PARP signaling pathway. The RPL34 promotes cell survival in GBM and could be a potential therapeutic target for GBM.

Keywords: Apoptosis; BAD; Cleaved PARP; Glioma; Proliferation; RPL34.

MeSH terms

  • Apoptosis
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / metabolism
  • Brain Neoplasms* / pathology
  • Cell Line, Tumor
  • Cell Proliferation / physiology
  • Glioblastoma* / genetics
  • Glioblastoma* / metabolism
  • Glioblastoma* / pathology
  • Glioma* / metabolism
  • Humans
  • Ribosomal Protein L3* / biosynthesis
  • Ribosomal Protein L3* / genetics
  • Ribosomal Protein L3* / metabolism
  • Ribosomal Proteins / genetics

Substances

  • RPL3 protein, human
  • Ribosomal Protein L3
  • Ribosomal Proteins